Ratcliff 2014.
Study characteristics | ||
Methods | CCT 3‐arm parallel‐group design |
|
Participants | Adult cancer patients who had undergone hematopoietic stem cell transplant Type of cancer: leukemia (n = 57, 63.3%), lymphoma (n = 13, 14.4%), other (n = 20, 22.2%) Total N randomized: 90 N randomized to music therapy group: 29 N randomized to unstructured music group: 30 (not used in this review) N randomized to control group: 31 N analyzed in music therapy group: 29 N analyzed in unstructured music group: 30 (not used in this review) N analyzed in control group: 31 Mean age: 44.3 years Sex: 47 (52%) female, 43 (48%) male Ethnicity: 59 (65.5%) white, 7 (7.8%) African‐American, 11 (12.2%) Latino, 4 (4.4%) Asian, 9 (10%) other Setting: outpatient or inpatient in transition to outpatient setting Country: USA |
|
Interventions | 3 study groups:
Music selections provided: patient‐preferred music selected from a researcher provided database Number of sessions: 4 Length of sessions: 50 min Categorized as music therapy |
|
Outcomes | Mood (POMS‐Short Form): change score (computed by JB) Quality of Life (FACIT‐G and FACIT‐BMT): change scores Cancer‐related symptoms (MD Anderson Symptom Inventory): not included in meta‐analysis |
|
Notes | — | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | "Patients were randomly assigned to one of three groups: (1) ISO‐principle music therapy (MT) group, (2) unstructured music (UM) group, and (3) usual care (UC) control group" (p. 2). |
Allocation concealment (selection bias) | Unclear risk | Not reported |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | Blinding of music therapist and participants was not possible. |
Blinding of outcome assessment (detection bias) Objective outcomes | Low risk | This study did not include objective outcomes. |
Blinding of outcome assessment (detection bias) Subjective outcomes | High risk | Self‐report measures were used for subjective outcomes. |
Incomplete outcome data (attrition bias) All outcomes | High risk | At the 1‐week follow‐up, there was 8.4% attrition. At the 4‐ week follow‐up, there was 27% attrition (additional data received from Dr. Lorenzo). |
Selective reporting (reporting bias) | High risk | "...blood samples were drawn but results will be reported in future manuscript." (p. 3). |
Other bias | Low risk | "This research was funded in part by a grant from The Maurice Amado Foundation, by Cancer Center Support Grant CA016672 from the National Institutes of Health, and by a cancer prevention fellowship for Chelsea Ratcliff supported by the National Cancer Institute Grant R25T CA057730, Shine Chang, Ph.D., Principal Investigator" (p. 8). |